
Publication
United States Corporate Transparency Act off again
The US Corporate Transparency Act (CTA) is a law that requires companies to disclose information on their beneficial owners.
Europe | Publication | March 2025
On February 26, 2025, the European Commission (Commission) published a legislative proposal with respect to the Carbon Border Adjustment Mechanism (CBAM) as part of the Omnibus Sustainability package. The proposal consists of over twenty amendments to the EU CBAM legislation, Regulation (EU) 2023/956 (the Regulation). With this proposal, the Commission aims to reduce the number of businesses impacted by CBAM by 90% and the compliance and financial burden (temporarily) for those in scope of CBAM. In this tax alert, we provide you with a recapitulative summary of CBAM, discuss the most relevant changes and offer practical guidance.
CBAM is a carbon adjustment on the importation into the EU of designated goods based on the CO2 emissions in the production process outside the EU. CBAM was adopted on May 17, 2023 and has been gradually introduced (and in force) since October 1, 2023. The designated goods are goods falling in the following categories: iron and steel, cement, fertilizers, aluminum, electricity and hydrogen (collectively: CBAM goods).
The aim of CBAM is to prevent the risk of carbon leakage and to encourage the reduction of emissions by producers in non-EU countries. Producers within the EU have to purchase emission allowances for the CO2 emissions of their products under the EU Emissions Trading System (EU ETS). When fully implemented, the CBAM price adjustment is intended to create a level playing field and ensure that EU producers no longer face a competitive disadvantage when importing from non-EU countries with lower climate standards.
CBAM applies to importers (declarants) of designated goods. A declarant could be described as the EU equivalent to an ‘importer of record’. Specifically, a declarant for EU customs and CBAM purposes is the person lodging a customs declaration in their own name and on their own behalf or, in case of indirect customs representation, the person on whose behalf a customs declaration is lodged.
Under the current CBAM rules, small quantities of imported CBAM goods may be automatically exempt from the CBAM reporting obligation provided the de minimis exemption applies. The de minimis exemption applies to consignments in which the total intrinsic value of the CBAM goods does not exceed EUR 150. Therefore, the overall value of the total CBAM goods in one consignment has to be considered, and if that value is above EUR 150, then the de minimis exemption does not apply. EU guidance confirms that for the exemption it is not relevant if different types of CBAM goods are imported in one consignment. If the overall value is above EUR 150, the de minimis exemption does not apply and the consignment must be reported.
As noted, the proposal covers over twenty changes to the Regulation. In our view, the most notable changes of the Regulation are as follows:
Changing from a de minimis monetary threshold to a mass threshold is in our view a welcome change. As noted, according to the Commission this would exempt around 90% of the importers of CBAM goods from the CBAM obligations. For businesses importing CBAM goods into the EU it is therefore important to assess whether they benefit from the new exemption or are part of the 10% of importers still in scope of CBAM.
If below the mass threshold, continuously monitoring is required to check that the 50 tonnes annual threshold is not exceeded in any given calendar year. In this respect, it should be emphasized that it artificially splitting shipments to avoid exceeding the mass threshold would be considered circumvention and addressed by the Commission accordingly – see before.
Initially, the proposed legislation was reported on various media outlets as a postponement of CBAM for another year. However, the transition period has not changed under the proposal, so that the requirement under the definitive CBAM regime of having CBAM certificates still applies. As such, the postponement of the sale of the CBAM certificates, while welcome, can be described as a deferral of payment for the CBAM certificates and therefore only a temporary cash flow benefit. Similarly, the reduction of the CBAM certificate ratio from 80% to 50% would provide some financial relief.
While the Regulation has direct effect (i.e. it does not need to be transposed into national law), it remains to be seen how the various EU authorities will enforce the CBAM rules, and in particular the penalty provisions. The relevant respective clause is phrased in a discretionary way (“The competent authority may decrease the amount of the penalty …”). The option for the EU authorities to decrease the penalties based on various circumstances could still be beneficial for businesses which are unintentionally non-compliant. Furthermore, conversely, intentional non-compliance could result in a penalty up to five times the so-called excess emissions penalty.
In summary, CBAM is not postponed and the transition period will end on 31 December 2025. As such, the legislative changes should be a reminder for businesses looking to import CBAM goods into the EU to check whether they benefit from the mass exemption or they should start preparing for the CBAM definitive regime. As a closing thought, CBAM may also affect businesses not importing CBAM goods themselves. If such businesses have counterparties who do import CBAM goods, the increased cost of import may impact prices in general.
Publication
The US Corporate Transparency Act (CTA) is a law that requires companies to disclose information on their beneficial owners.
Publication
Health Canada has published a Notice of Intent to publish a ministerial order to exempt natural health products (NHPs) licensed between June 21, 2025, and June 21, 2028, from labelling requirements that are set to come into force this summer under the Natural Health Products Regulations (NHPR).
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025